The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Konverge 40mg/5mg film-coated tablets

40/5 mg/mg Film-coated tablet

IMED Healthcare Ltd.PPA1463/104/002

Main Information

Trade NameKonverge 40mg/5mg film-coated tablets
Active SubstancesAmlodipine besylate
Olmesartan medoxomil
Strength40/5 mg/mg
Dosage FormFilm-coated tablet
Licence HolderIMED Healthcare Ltd.
Licence NumberPPA1463/104/002

Group Information

ATC CodeC09DB Angiotensin II antagonists and calcium channel blockers
C09DB02 olmesartan medoxomil and amlodipine


Withdrawn Date26/08/2021
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Generics Information

Interchangeable List CodeIC0046-094-003
Interchangeable List DocumentPDF of Interchangeable List
« Back